Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin.
View/ Open
Date
1994Author
Tyndall, MW
Agoki, E
Plummer, FA
Malisa, W
Ndinya-Achola, JO
Ronald, AR
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
BACKGROUND AND OBJECTIVES:
Chancroid is endemic in sub-Saharan Africa and enhances the sexual transmission of the human immunodeficiency virus Type 1 (HIV-1). Azithromycin is an orally absorbed macrolide antibiotic that is active against Haemophilus ducreyi, the causative agent of chancroid, and has pharmacokinetic properties that are suitable for single dosing.
STUDY DESIGN:
In a randomized single-blinded study of 127 men presenting to a referral STD clinic with culture proven chancroid, we compared the efficacy of azithromycin, administered as a single 1 g dose, with erythromycin 500 mg given 4 times daily for 7 days.
RESULTS:
Cure rates were 89% (73 of 82) in the azithromycin group and 91% (41 of 45) in the erythromycin group. A failure to respond to treatment was associated with HIV-1 seropositivity and a lack of circumcision. Both regimens were well tolerated.
CONCLUSIONS:
Azithromycin, given as a single 1 g oral dose, is an effective treatment for chancroid in men, and offers major prescribing advantages over erythromycin
URI
http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/7974076http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16921
Citation
Sex Transm Dis. 1994 Jul-Aug;21(4):231-4Publisher
WHO Collaborating Centre for Research and Training in Sexually Transmitted Diseases Department of Medical Microbiology, University of Nairobi, Kenya
Collections
- Faculty of Health Sciences (FHS) [10377]